During the past decade, Hôpital Saint Eloi conducted 172 clinical trials. In the 10-year time frame, 172 clinical trials started and 39 clinical trials were completed, i.e. on average, 22.7% percent of trials that started reached the finish line to date. In the past 5 years, 56 clinical trials started and 24 clinical trials were completed. i.e. 42.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hôpital Saint Eloi" #1 sponsor was "Centre Hospitalier Universitaire de Nīmes" with 18 trials, followed by "The Lymphoma Academic Research Organisation" with 18 trials sponsored, "University Hospital, Montpellier" with 13 trials sponsored, "Gilead Sciences" with 11 trials sponsored and "Hoffmann-La Roche" with 11 trials sponsored. Other sponsors include 190 different institutions and companies that sponsored additional 97 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hôpital Saint Eloi" #1 collaborator was "AbbVie" with 6 trials as a collaborator, "Bristol-Myers Squibb" with 5 trials as a collaborator, "Ministry of Health, France" with 5 trials as a collaborator, "Gilead Sciences" with 4 trials as a collaborator and "Merck Sharp & Dohme LLC" with 4 trials as a collaborator. Other collaborators include 90 different institutions and companies that were collaborators in the rest 81 trials.

According to Clinical.Site data, the most researched conditions in "Hôpital Saint Eloi" are "Ulcerative Colitis" (18 trials), "Multiple Myeloma" (13 trials), "Acute Myeloid Leukemia" (8 trials), "Lymphoma, Non-Hodgkin" (7 trials) and "Crohn's Disease" (6 trials). Many other conditions were trialed in "Hôpital Saint Eloi" in a lesser frequency.

Most popular intervention types in "Hôpital Saint Eloi" are "Drug" (166 trials), "Other" (28 trials), "Biological" (27 trials), "Procedure" (19 trials) and "Device" (16 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (27 trials), "Rituximab" (14 trials), "Obinutuzumab" (9 trials), "Cyclophosphamide" (8 trials) and "Doxorubicin" (8 trials). Other intervention names were less common.

The vast majority of trials in "Hôpital Saint Eloi" are 256 trials for "All" genders, 7 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are 101 active trials in "Hôpital Saint Eloi". 1 are not yet recruiting, 62 are recruiting, 37 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 130 completed trials in Hôpital Saint Eloi, undefined suspended trials, and 20 terminated clinical trials to date.

Out of the total trials that were conducted in Hôpital Saint Eloi, 28 "Phase 1" clinical trials were conducted, 82 "Phase 2" clinical trials and 82 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 36 trials that are defined as “Not Applicable".

Hôpital Saint Eloi has several departments that took part in Clinical trials: "CHU Saint Eloi; Service d'Hématologie Clinique" - 4 trials, "Hopital Saint Eloi; Hematologie Oncologie Medicale" - 4 trials, "Hôpital Lapeyronie - Département Anesthésie Réanimation A" - 4 trials, "CHU de Montpellier" - 4 trials, "IURC - Laboratoire de Biostatistique d'Epidémiologie et de Recherche Clinique" - 2 trials, "Hôpital Arnaud de Villeneuve; Néphrologie pédiatrique" - 2 trials, "Heart and vascular diseases service" - 2 trials, "CHRU Montpellier; SMPEA Peyre Plantade Centre de Ressources Autisme" - 2 trials, "Hopital Saint-Eloi; Hepatologie-Gastro-Enterologie" - 2 trials, "Hopital Lapeyronie; Nephrologie" - 2 trials, "Hôpital Arnaud De Villeneuve - Service des Maladies Respiratoires" - 2 trials